Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ACP1 | P24666 | 2/20 | 0.31 |
| ▸ | CDC25B | P30305 | 2/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2499788 | 0.98 | LMNA (0.52) | LMNAHSD17B10PTPN1ALDH1A1NPC1 | |
| SCHEMBL2804681 | 0.95 | LMNA (0.53) | LMNAHSD17B10PTPN1ALDH1A1NPC1 | |
| SCHEMBL13055682 | 0.91 | LMNA (0.52) | LMNAHSD17B10PTPN1ALDH1A1NPC1 | |
| SCHEMBL13311937 | 0.81 | LMNA (0.53) | LMNAHSD17B10PTPN1ALDH1A1NPC1 | |
| SCHEMBL3751031 | 0.77 | LMNA (0.41) | LMNAHSD17B10PTPN1 | |
| SCHEMBL9730908 | 0.71 | — | — | |
| SCHEMBL4951420 | 0.70 | HSD17B10 (1.00) | LMNAHSD17B10PTPN1ALDH1A1NPC1 | |
| SCHEMBL28922793 | 0.69 | LMNA (0.45) | LMNAHSD17B10PTPN1ALDH1A1NPC1 | |
| SCHEMBL7815255 | 0.68 | LMNA (0.41) | LMNAHSD17B10PTPN1ALDH1A1 | |
| SCHEMBL11001381 | 0.67 | LMNA (0.56) | LMNAHSD17B10PTPN1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2021-05-06 | — | — | US | disclosed |
| EP-2268140-B1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-2167621-B1 | ORGANIC COMPOUNDS AS ODORANTS | GIVAUDAN SA (CH) | 2017-10-11 | — | — | EP | disclosed |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2016-05-19 | — | — | US | disclosed |
| US-9212155-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9206143-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9012391-B2 | Organic compounds | GIVAUDAN SA (CH) | 2015-04-21 | — | — | US | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046138-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20100292128-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| EP-2167621-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008151455-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | HRH4, HRH2, HRH1 | LMNA 4752/4885HSD17B10 3400/4885PTPN1 2207/4885 |
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | LMNA 1000/4885HSD17B10 1458/4885PTPN1 4209/4885 |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GAP43, CHRNA10, CHRNA6 | LMNA 2068/4885HSD17B10 1525/4885PTPN1 2684/4885 |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | HRH4, HRH2, HRH1 | LMNA 4814/4885HSD17B10 3293/4885PTPN1 2021/4885 |
| US-20100292128-A1 | Organic Compounds | TRPA1, FASN, OR10J3 | LMNA 1886/4885HSD17B10 47/4885PTPN1 4848/4885 |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | LMNA 1000/4885HSD17B10 1458/4885PTPN1 4209/4885 |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | LMNA 680/4885HSD17B10 1825/4885PTPN1 3902/4885 |
| US-20110046138-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | CHRNA10, CHRNA6, GAP43 | LMNA 2144/4885HSD17B10 1633/4885PTPN1 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.